The relationship between fibroblast growth factor 23 and osteoporosis in postmenopausal women

Minerva Medica

Volumn 104, Issue 5, 2013, Pages 497-504

  Celik, E ^a   Guzel, S ^a   Abali, R ^a   Guzelant, A Y ^a   Celik Guzel, E ^a   Kucukyalcin V ^a  

^a NAMIK KEMAL UNIVERSITY   (Turkey)

Author keywords

Fibroblast growth factor 23; Hydroxyproline; Osteocalcin; Osteoporosis, postmenopausal; Vitamin D

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM PHOSPHATE; FIBROBLAST GROWTH FACTOR 23; HYDROXYPROLINE; OSTEOCALCIN; PARATHYROID HORMONE; VITAMIN D;

ADULT; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MENOPAUSE; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW;

ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; BONE REMODELING; CALCIUM; CASE-CONTROL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYDROXYPROLINE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

EID: 84890016966     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Rosen CJ, Kessenich CR. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases. Drugs 1996;51:537-51
2. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646-50.
3. Garnero P, Delmas PD. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 2004;4:50-63. (Pubitemid 38714795)
4. Riggs BL, Khosla S, Melton LJ, 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002;23:279-302. (Pubitemid 34651948)
5. Cannata-Andia JB, Carrillo-Lopez N, Naves-Diaz M. Estrogens and bone disease in chronic kidney disease: role of FGF23. Curr Opin Nephrol Hypertens 2010;19:354-8.
6. Venken K, Callewaert F, Boonen S, Vanderschueren D. Sex hormones, their receptors and bone health. Osteoporos Int 2008;19:1517-25.
7. Michael H, Harkonen PL, Vaananen HK, Hentunen TA. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res 2005;20:2224-32. (Pubitemid 41698785)
8. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000;21:115-37. (Pubitemid 32275592)
9. Lerner UH. Bone remodeling in post-menopausal osteoporosis. J Dent Res 2006;85:584-95. (Pubitemid 44085947)
10. Liel Y, Shany S, Smirnoff P, Schwartz B. Estrogen increases 1,25-dihydroxyvitamin D receptors expression and bioresponse in the rat duodenal mucosa. Endocrinology 1999;140:280-5. (Pubitemid 29011170)
11. Ten Bolscher M, Netelenbos JC, Barto R, Van Buuren LM, Van der vijgh WJ. Estrogen regulation of intestinal calcium absorption in the intact and ovariectomized adult rat. J Bone Miner Res 1999;14:1197-202. (Pubitemid 29314064)
12. Irnaten M, Blanchard-Gutton N, Praetorius J, Harvey BJ. Rapid effects of 17beta-estradiol on TRPV5 epithelial Ca2+ channels in rat renal cells. Steroids 2009;74:642-9.
13. Faroqui S, Levi M, Soleimani M, Amlal H. Estrogen downregulates the proximal tubule type IIa sodium phosphate cotransporter causing phosphate wasting and hypophosphatemia. Kidney Int 2008;73:1141-50. (Pubitemid 351620434)
14. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000;277:494-8.
15. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003;112:683-92. (Pubitemid 38057709)
16. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429-35. (Pubitemid 38787398)
17. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1-129.
18. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996;29:225-9. (Pubitemid 26142071)
19. Garnero P, Mulleman D, Munoz F, Sornay-Rendu E, Delmas PD. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study. J Bone Miner Res 2003;18:1789-94. (Pubitemid 37322556)
20. Ix JH, Chonchol M, Laughlin GA, Shlipak MG, Whooley MA. Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study. Am J Kidney Dis 2011;58:737-45.
21. Zhang R, Lu Y, Ye L, Yuan B, Yu S, Qin C, et al. Unique roles of phosphorus in endochondral bone formation and osteocyte maturation. J Bone Miner Res 2011;26:1047-56.
22. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004;23:421-32. (Pubitemid 39576657)
23. Wang H, Yoshiko Y, Yamamoto R, Minamizaki T, Kozai K, Tanne K et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 2008;23:939-48. (Pubitemid 351768812)
24. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006;17:1305-15. (Pubitemid 43673410)
25. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 2009;150:4835-45.
26. Razzaque MS, St-Arnaud R, Taguchi T, Lanske B. FGF-23, vitamin D and calcification: the unholy triad. Nephrol Dial Transplant 2005;20:2032-5. (Pubitemid 41510074)
27. Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009;94:511-7.
28. Hollberg K, Marsell R, Norgard M, Larsson T, Jonsson KB, Andersson G. Osteoclast polarization is not required for degradation of bone matrix in rachitic FGF23 transgenic mice. Bone 2008;42:1111-21.
29. Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007;18:2683-8. (Pubitemid 47531195)
30. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005;146:4577-83. (Pubitemid 41446595)
31. Goebel S, Lienau J, Rammoser U, Seefried L, Wintgens KF, Seufert J, et al. FGF23 is a putative marker for bone healing and regeneration. J Orthop Res 2009;27:1141-6.
32. Sridharan M, Cheung J, Moore AE, Frost ML, Fraser WD, Fogelman I et al. Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation. Calcif Tissue Int 2010;87:398-405.
33. Ohta H, Ikeda T, Masuzawa T, Makita K, Suda Y, Nozawa S. Differences in axial bone mineral density, serum levels of sex steroids, and bone metabolism between postmenopausal and age- and body size-matched premenopausal subjects. Bone 1993;14:111-6. (Pubitemid 23098957)
34. Iki M, Morita A, Ikeda Y, Sato Y, Akiba T, Matsumoto T et al. Biochemical markers of bone turnover predict bone loss in perimenopausal women but not in postmenopausal women-the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos Int 2006;17:1086-95. (Pubitemid 43864861)
35. Nancy E. Lane PNS. The epidemiology of osteoporotic fractures. Osteoporosis and the osteoporosis of rheumatic diseases. Philadelphia, PA: Mosby-Elsevier; 2006.